[Cancer Cell] TGF-β antagonist opens tumors to immune attack by Medpacto, Korea
A study published in Cancer Cell describes an experimental drug that breaks down the barrier protecting solid tumors, allowing killer T cells to attack. The drug, FEBP-sTβRII, changes the activity of genes in the blood and reprograms immune cells to recognize cancer, leading to durable tumor immunity.